Emerging therapeutic strategies for chronic pain

Emerging Drugs

Volumn 5, Issue 4, 2000, Pages 385-413

  Abrahams, M J ^a   Munglani, R ^a  

^a WEST SUFFOLK HOSPITAL   (United Kingdom)

Author keywords

Adenosine kinase inhibitors; AMPA receptor antagonists; Bradykinin receptor antagonists; Cannabinoid receptor agonists; Capsaicin; Cholinergic receptor agonists; Chronic pain; COX 2 inhibitors; Gabapentin; N type calcium channel blockers; NGF receptor antagonists; NK 1 receptor antagonists; NMDA receptor antagonists; NOS inhibitors; P2X receptor antagonists; Somatostatin analogues; Therapeutic targets; TTXi receptor antagonists; VR 1 receptor agonists; opioid receptor agonists

Indexed keywords

1F 160687; 2 [[4 [4 (AMINOIMINOMETHYL)BENZOYL] 1 PIPERAZINYL]CARBONYL] 1 [2,4 DICHLORO 3 [(2,4 DIMETHYL 8 QUINOLINYL)OXYMETHYL]PHENYLSULFONYL]PYRROLIDINE; 3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; 3 BROMO 8 [2,6 DICHLORO 3 [N [4 (N,N DIMETHYLCARBAMOYL)CINNAMIDOACETYL] N METHYLAMINO]BENZYLOXY] 2 METHYLIMIDAZO[1,2 A]PYRIDINE; ADENOSINE KINASE INHIBITOR; ADL 1 0101; ADL 21294; AMPA RECEPTOR AGONIST; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ASIMADOLINE; BCH 2687; BRADYKININ ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID RECEPTOR ANTAGONIST; CAPSAICIN; CAPSAICIN DERIVATIVE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIS CAPSAICIN; CO 10282; CYCLOOXYGENASE 2 INHIBITOR; FE 200041; FR 184280; GABAPENTIN; GALANIN; KAPPA OPIATE RECEPTOR ANTAGONIST; LOPERAMIDE; MEN 11270; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NPC 18521; NPC 18884; OPIATE AGONIST; PROSTANOID RECEPTOR ANTAGONIST; PS 0209990; PS 322853; PURINE P2X RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; RESINFERATOXIN; RESINIFERATOXIN; RIFUZOLE; SODIUM CHANNEL BLOCKING AGENT; SOMATOSTATIN DERIVATIVE; TACHYKININ RECEPTOR ANTAGONIST; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR ANTAGONIST;

CHRONIC PAIN; CLINICAL TRIAL; DRUG CHOICE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; NEUROANATOMY; NEUROPHYSIOLOGY; NONHUMAN; REVIEW; SENSITIZATION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0034491306     PISSN: 13619195     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.5.4.385     Document Type: Review

References (190)

1. Plasticity: Implications for opioid and other pharmacological interventions in specific pain states
2. A new perspective on signal transduction in neuropathic pain
3. New paths to pain relief
4. The TIPS/TINS lecture: The molecular biology of the mammalian glutamate receptor channels
5. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states
6. Spatial distribution of nociceptive processing in the rat spinal cord
7. The capsaicin receptor: A heat-activated channel in the pain pathway
8. Sensory neuron-specific actions of capsaicin: Mechanisms and applications
9. Capsaicin activates a nonselective cation channel in cultured neonatal rat dorsal root ganglion neurons
10. Chemical activators of sensory neurons
11. Capsaicin: Cellular targets, mechanisms of action and selectivity for thin sensory neurons
12. Inhibition of calcineurin inhibits the desensitization of capsaicin-evoked currents in cultured dorsal root ganglion neurones from adult rats
13. Neuropharmacological mechanisms of capsaicin and related substances
14. Topical capsaicin in humans: Parallel loss of epidermal nerve fibers and pain sensation
15. Inflammatory mediators at low pH activate capsaicin receptors in cultured sensory neurons from newborn rats
16. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia
17. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: A randomized, double-blind, placebo-controlled study
18. Antinociception induced by civamide, an orally active capsaicin analogue
19. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
20. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
21. The control of pain in peripheral tissue by opioids
22. Interleukin-1β and corticotrophin releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissues
23. Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue
24. Peripheral opioid analgesia
25. Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist - Loperamide
26. Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans
27. ATP in human skin elicits a dose-related pain response which is potentiated under conditions of hyperalgesia
28. Pharmacological characterization of recombinant human and rat P2X receptor subtypes
29. The role of purines in nociception
30. Characterization of a P2X-purinoceptor in cultured neurones of the rat dorsal root ganglia
31. 3 receptor subunits can account for ATP-gated currents in sensory neurons
32. Noradrenaline and ATP as cotransmitters in sympathetic nerves
33. Activation by P2X purinoceptor agonists of sensory nerves innervating the rat knee joint
34. Effects of spinally administered P2X receptor agonists and antagonists on the responses of dorsal horn neurones recorded in normal, carrageenan-inflamed and neuropathic rats
35. Antagonist effects on human P2X(7) receptor-mediated cellular accumulation of YO-PRO-1
36. 7 receptor
37. Peripheral antinociceptive effect of an adenosine kinase inhibitor, with augmentation by an adenosine deaminase inhibitor, in the rat formalin test
38. An adenosine kinase inhibitor attenuates tactile allodynia in a rat model of diabetic neuropathic pain
39. Adenosine kinase inhibitors [review]
40. 1 receptors
41. Peripheral and central mechanisms of NGF induced hyperalgesia
42. Chronic pain is associated with increased TrkA immunoreactivity in spinoreticular neurons
43. The biological effects of endogenous NGF in adult sensory neurones revealed by a trk-A-IgG fusion molecule
44. Endogenous nerve growth factor regulates the sensitivity of nociceptors in the adult rat
45. Intrathecally injected neurotrophins and the release of substance P from the rat isolated spinal cord
46. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat
47. Three types of sodium channels in adult rat dorsal root ganglion neurons
48. A tetrodotoxin-resistant sodium channel expressed by sensory neurones
49. Voltage- and use-dependent inhibition of Na+ channels in rat sensory neurones by 4030W92, a new antihyperalgesic agent
50. Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels
51. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways
52. Human cyclo-oxygenase-1 cDNA
53. Cloning two isoforms of rat cyclooxygenase: Differential regulation of their expression
54. Comparison of Rofecoxib and Celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator- controlled clinical trial
55. MK-966 versus naproxen sodium 550mg in post-surgical dental pain
56. VIOXX 50mg versus ibuprofen 400mg in post-surgical dental pain
57. The safety profile, tolerability and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
58. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
59. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomised controlled trial
60. Bradykinin receptors: Pharmacological properties and biological roles
61. Activation of guanylate cyclase by bradykinin in rat sensory neurones is mediated by calcium influx: Possible role of the increase in cyclic GMP
62. Bradykinin-induced activation of nociceptors: Receptor and mechanistic studies on the neonatal rat spinal cord-tail preparation in vitro
63. 2 kinin receptors in formalin-induced nociceptive response in the mouse
64. 8)-Bk and HOE 140, in two models of persistent hyperalgesia in the rat
65. 2 receptor antagonist
66. 1 receptor mediated nociception
67. 2+ in rat central neurones
68. NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology
69. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)
70. The glycine site of the NMDA receptor - Five years on
71. NMDA receptors: From genes to channels
72. Glutamate in CNS disorders
73. Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine in mice
74. Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist
75. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: Correlation with restricted localisation of NR2B subunit in dorsal horn
76. Cutaneous hyperalgesia: Contributions of the peripheral and central nervous systems to the increase in pain sensitivity after injury
77. Preinjury treatment with morphine or ketamine inhibits the development of experimentally induced secondary hyperalgesia in man
78. NMDA-receptor antagonists in neuropathic pain: Experimental methods to clinical trials [review]
79. Ketamine reduces muscle pan, temporal summation and referred pain in fibromyalgia patients
80. Premedication with dextromethorphan provides posthemorrhoidectomy pain relief
81. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes? [review]
82. NMDA receptor antagonists: Interactions with opioids
83. Synthesis and pharmacological properties of novel glycine antagonists [review]
84. AMPA/kainate receptor antagonists as novel analgesic agents [editorial]
85. Intrathecal non-NMDA excitatory amino acid antagonists inhibit pain behaviours in a rat model of postoperative pain
86. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans
87. Neurotransmitter candidates of somatosensory primary afferent fibers
88. Characterisation of neurokinin binding sites in rat brain membranes using highly selective ligands
89. Transgenic studies of pain
90. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor
91. Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons
92. Reversal of behavioural and electrophysiological correlates of experimental peripheral neuropathy by the NK1 receptor antagonist GR205171 in rats
93. LY303870, a centrally active neurokinin-1 antagonist with a long duration of action
94. 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N-methyla mide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models
95. NK1 (substance P) receptor antagonists - Why are they not analgesic in humans? [review]
96. Neurokinin antagonists aspotential agents for use in pain management
97. The broad spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR 203040
98. Effect of topical administration of L-arginine on formalin-induced nociception in the mouse
99. The nitric oxide-cyclic GMC pathway is required for nociceptive signalling at specific loci within the somatosensory pathway
100. Modulation of acute inflammation by endogenous nitric oxide
101. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation
102. Sodium nitroprusside evokes the release of immunoreactive calcitonin gene-related peptide and substance P from dorsal horn slices via nitric oxide-dependent and nitric oxide-independent mechanisms
103. Inhibition of nitric oxide synthase enhances antinociception mediated by mu, delta and kappa opioid receptors in acute and prolonged pain in the rat spinal cord
104. Nitric oxide releases acetylcholine in the basal forebrain
105. Endogenous nitric oxide is required for tonic cholinergic inhibition of spinal mechanical transmission
106. Antinociceptive properties and nitric oxide synthase inhibitory action of new ruthenium complexes
107. Inhibition of inducible nitric oxide synthase in persistent pain
108. Direct binding of G-protein βγ complex to voltage-dependent calcium channels
109. 2+ channels in the rat periaqueductal grey neurons by μ-type opioid agonist
110. Deltaopioid receptor agonists produce antinociception and [35S]GTPgammaS binding in mu receptor knockout mice
111. The efficacy of delta-opioid receptor-selective drugs [review]
112. Nonpeptide analogues of dynorphin A(1-8): Design, synthesis, an pharmacological evaluation of kappa-selective agonists
113. Antinociceptive activity of [beta-methyl-2′, 6′-dimethyltyrosine(1)]-substituted cyclic [D-Pen(5)] Enkephalin and [D-Ala(2),Asp(4)] Deltorphin analogs
114. Distinct inhibitory effects of spinal endomorphin-1 and endomorphin-2 on evoked dorsal horn responses in the rat
115. A potent and selective endogenous agonist for the μ-opiate receptor
116. Differential mechanisms mediating descending pain controls for antinociception induced by supraspinally administered endomorphin-1 and endomorphin-2 in the mouse
117. Pain-suppressive effects on various nociceptive stimuli (thermal, chemical, electrical and inflammatory) of the first orally active enkephalin-metabolizing enzyme inhibitor RB 120
118. B receptor antagonist L-365,260 in rat spinal cord
119. Cholecystokinin and morphine analgesia: Variations on a theme
120. Cholecystokinin
121. Biological actions of cholecystokinin
122. Cholecystokinin octapeptide reverses μ-opioid-receptor-mediated inhibition of calcium current in rat dorsal root ganglion neurons
123. Cholecystokinin inhibits peripheral opioid analgesia in inflamed tissue
124. Marked increase in cholecystokinin B receptor messenger RNA levels in rat dorsal root ganglia after peripheral axotomy
125. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation
126. The cholecystokinin antagonist proglumide enhances the analgesic efficacy of morphine in humans with chronic benign pain
127. Neuronal nicotinic receptors: New targets in the treatment of pain
128. Nociceptive and antinociceptive responses to intrathecal administered nicotinic agents
129. Antinociception opioids and the cholinergic system
130. Muscarinic-mediated analgesia
131. Intravenous morphine increases release of nitric oxide from spinal cord by an alpha-arenergic and cholinergic mechanism
132. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors
133. Nicotinic cholinergic receptors: Potential targets for inflammatory pain relief
134. Antinociceptive effects of the novel neuronal nicotinic acetyl choline receptor agonist, ABT-594, in mice
135. Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain
136. The identification of novel structural compound classes exhibiting high affinity for neuronal nicotinic acetylcholine receptors and analgesic efficacy in preclinical models of pain
137. Therapeutic potential for adenosine receptor activation in ischaemic brain injury
138. Adenosine inhibition of synaptic transmission in the substantia gelatinosa
139. Adenosine inhibits action potential-dependent release of calcitonin gene-related peptide and substance P-like immunoreactivites from primary afferents in rat spinal cord
140. Intrathecal adenosine analog administration reduces substance P in cerebrospinal fluid along with behavioural effects that suggest antinociception in rats
141. Classification of adenosine receptors mediating antinociception in the rat spinal cord
142. The control of adenosine concentration in polymorphonuclear leukocytes, cultured cells and isolated perfused heart from the rat
143. 2 receptors
144. Cannabinoid CB(1) receptor expression in rat spinal cord
145. Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist
146. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects
147. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice
148. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: Possible mechanisms for interaction with morphine
149. Synergistic interactions of endogenous opioids and cannabinoid systems
150. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats
151. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain
152. 2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
153. The immunocytochemical localization of somatostatin-containing neurons in the rat central nervous system
154. Immunocytochemical studies of somatostatin neurons in brain
155. Effects of intrathecal nonnarcotic analgesics on chronic tactile allodynia in rats: Alpha-2-agonists versus somatostatin analog
156. Evidence for a central long-lasting antinociceptive effect of vapreotide, an analog of somatostatin involving an opioidergic mechanism
157. Pain affect encoded in human anterior cingulate but not somatosensory cortex
158. Identification and characterization of novel somatostatin antagonists
159. Opioid peptides: Simultaneous delta agonism and mu antagonism in somatostatin analogues
160. Classification of calcium channels and the sites of action of drugs modifying channel function
161. The role of NMDA receptor-operated calcium channels in persistent nociception after formalin-induced tissue injury
162. Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons
163. Molecular mechanisms underlying the regulation of proenkephalin gene expression in cultured spinal cord cells
164. Blockade of spinal N- and P-type, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurones produced by subcutaneous formalin inflammation
165. ω-Conotoxin sensitivity and presynaptic inhibition of glutamatergic neurotransmission in vitro
166. Voltage-sensitive calcium channels in spinal nociceptive processing: Blockade of N- and P-type channels inhibits formalin-induced nociception
167. Voltage-dependent calcium channel involvement in NMDA-induced activation of NOS
168. Gabapentin (GBP, Neurontin) reduces pain in diabetics with painful peripheral neuropathy: Results of a double blind, placebo-controlled trial (945-210)
169. 2δ subunit of a calcium channel
170. Spinal gabapentin is antinociceptive in the rat formalin test
171. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain
172. The antiallodynic effects of amitriptylline, gabapentin and lidocaine in a rat model of neuropathic pain
173. Randomised double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain
174. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial
175. Gabapentin for the treatment of postherpetic neuralgia: A randomised controlled trial
176. Adverse effects associated with the intrathecal administration of ziconotide
177. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociceptoin in rats
178. Blockade of N- and P/Q-typed calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation
179. Omega-agatoxin IVA, a P-type calcium channel antagonist, reduces nociceptive processing in spinal cord neurons with input from the inflamed but not from the normal knee joint - An electrophysiological study in the rat in vivo
180. Spinal application of omega-conotoxin GVIA, an N-type calcium channel antagonist, attenuates enhancement of dorsal spinal neuronal responses caused by intra-articular injection of mustard oil in the rat
181. Effects of radolmidine, a novel alpha2-adrenergic agonist compared with dexmedetomidine in different pain models in the rat
182. Increased neuropeptide Y (NPY)-like immunoreactivity in rat sensory neurons following peripheral axotomy
183. Effects of peripheral nerve injuries and tissue inflammation on the levels of neuropeptide Y-like immunoreactivity in rat primary afferent neurons
184. The effects of neuropeptide Y on the electrical properties of neurons
185. 1A agonists induce central cholinergic antinociception
186. 3 receptor antagonism in conscious rats
187. Inhibition of spinal protein kinase C reduces nerve injury-induced tactile allodynia in neuropathic rats
188. Heat-induced release of CGRP from isolated rat skin and effects of bradykinin and the protein kinase C activator PMA
189. Possible involvement of spinal protein kinase C in thermal allodynia and hyperalgesia in diabetic mice